Oxidized lipids and lipoproteins: Indices of risk or targets for management

Future Lipidology

Volumn 4, Issue 1, 2009, Pages 41-45

  Le, Ngoc Anh ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Cardiovascular risk; Oxidative stress; Oxidative susceptibility; Oxidized LDL; Oxidized lipoproteins; Postprandial lipermia

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; EPITOPE; GLIBENCLAMIDE; IMMUNOGLOBULIN M; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; REPAGLINIDE;

ABDOMINAL OBESITY; ARTERIAL WALL THICKNESS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENDOCYTOSIS; ENZYME ACTIVITY; ETHNICITY; EXERCISE; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INCIDENCE; ION EXCHANGE CHROMATOGRAPHY; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID HYDROLYSIS; LIPID OXIDATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; POSTPRANDIAL HYPERGLYCEMIA; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; REVIEW; SEX DIFFERENCE; UNSTABLE ANGINA PECTORIS;

EID: 67149146314     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584299.4.1.41     Document Type: Review

References (79)

1. Keys A, Blackburn H, Menotti A et al.: Coronary heart disease in seven countries. Circulation 41(Suppl. 1), 1-211 (1970).
2. Lipid Research Clinics Program: The LRC-CPPT results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365-374 (1984).
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cahin-Hemphill L: Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous: bypass grafts. JAMA 257, 3233-3240 (1987).
4. Andrews TC, Ballantyne CM, Hsia JA, Kramer-Statin JH: Achieving and maintaining NCEP LDL-cholesterol goal with five statins. Am. J. Med. 111, 185-191 (2001).
5. Deedwania P, Barter P, Carmena R et al.; for the Treating to New Targets Investigators: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919-928 (2006).
6. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy. Arch. Intern. Med. 166, 2307-2313 (2006).
7. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
8. Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of Cardiovascular disease. Circulation 103, 1813-1818 (2001).
9. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE) a randomized trial and-cohort study. JAMA 286, 64-70 (2001).
10. 2, hsCRP, and risk for incident coronary heart disease in middle aged men and women in the ARIC study. Circulation 109, 837-842 (2004).
11. 2 adds to risk prediction of incident coronary events by hsCRP in apparently healthy middle-aged men from the general population from the 14-yr follow-up of a large cohort from southern Germany. Circulation 110, 1903-1908 (2004).
12. Steinberg D, Parthasarathy S, Carew TE, Khoo JD, Witztum JL: Beyond cholesterol: modifications of LDL that increase its atherogenicity. N. Engl. J. Med. 320, 915-924 (1989).
13. Hazell LJ, Stocker R. Oxidation of LDL with hypochlorite cause transformation of the lipoprotein into a high-uptake form for macrophages. Biochem. J. 290, 165-172 (1993).
14. Navab M, Anantharamaiah GM, Reddy ST et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993-1007 (2004).
15. Avogaro P, Bon Bittolo G, Cazzolato G: Presence of a modified LDL in humans. Arteriosclerosis 8, 79-87 (1988).
16. Yla-Herttuala S, Palinski W, Rosenfeld ME et al.: Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84, 1086-1095 (1989).
17. Palinski W, Rosenfeld ME, Yla-Herttuala S et al.: LDL undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372-1376 (1989).
18. Itabe H, Yamamoto H, Imanaka T et al.: Sensitive detection of oxidatively modified LDL using a monoclonal antibody. J. Lipid Res. 37, 45-53 (1996).
19. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscl. Thromb. 14, 32-40 (1994).
20. Palinski W, Horkko S, Miller E et al.: Cloning of monoclonal antibodies to epitopes of oxidized lipoproteins from ApoE-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. J. Clin Invest. 98, 800-814 (1996).
21. McEneny J, O'Kane MJ, Moles KW et al.: VLDL subfractions in type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43, 485-493 (2000).
22. Mabile L, Salvayre R, Bonnafe M-J, Negre-Salvayre A: Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Free Rad. Biol. Med. 19, 599-607 (1995).
23. Nakajima K, Nakano T, Tanaka A: The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects of oxidized LDL and remnant lipoproteins in plasma. Clin. Chim. Acta 367, 36-47 (2006).
24. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381-1478 (2004).
25. Le N-A: Reducing oxidized lipids to prevent cardiovascular disease. Curr. Treat. Options Cardiovasc. Med. 10, 263-272 (2008).
26. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human LDL. Free Rad. Res. Commun. 6, 67-75 (1989).
27. Rae TD, Schmidt PJ, Pufahl RA et al.: Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284, 805-808 (1999)
28. Holvoet P, Donck J, Landelos M et al.:. Correlation between oxidized LDL and von Willebrand Factor in chronic renal failure. Thromb. Haemostasis 76, 663-669 (1996).
29. Tsimikas S: Measures of oxidative stress. Clin. Lab. Med. 26, 571-590 (2006).
30. Holvoet P, Kritchevsky SB, Tracy RP et al.: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the Health Aging and Body Composition cohort. Diabetes 53, 1068-1073 (2004).
31. Holvoet P, Lee D-H, Steffes M, Gross M, Jacobs DR Jr: Association between circulating oxidized LDL and incidence of metabolic syndrome. J. Am. Med. Assoc. 299, 2287-2293 (2008).
32. Holvoet P, Mertens A, Verhamme P et al.: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease Arterioscl. Thromb. Vasc. Biol. 21, 844-848 (2001).
33. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J: Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J. Intern. Med. 256, 413-320 (2004).
34. Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D; the Asklepios Investigators: Femoral plaques confound the association of circulating oxidized LDL with carotid atherosclerosis in a general population aged 35 to 55 years. The Asklepios Study. Arterioscl. Thromb. Vasc. Biol. 28, 1563-1568 (2008).
35. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR: The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194, 245-252 (2007).
36. Tsimikas S, Brilakis ES, Miller ER et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46-57 (2005).
37. Tsimikas S Kiechl S, Willeit J et al.: (Oxidized phospholipids predict the presence of carotid and femoral atherosclerosis and symptomatic cardiovascular disease. J. Am. Coll. Cardiol. 47, 2219-2228 (2006).
38. Kiechl S, Willeit J, Mayr M et al.: Oxidized phospholipids, Lp(a), Lp-PLA2 activity, and 10-year cardiovascular outcomes. Prospective results from the Bruneck Study. Arterioscl. Thromb. Vasc. Biol. 27, 1788-1795 (2007).
39. Salonen JT, Yla-Herttuala S, Yamamoto R et al.: Autoantibody against LDL and progression of carotid atherosclerosis. Lancet 339, 883-887 (1992).
40. Puurunen M, Manttari M, Manninen V et al.: Antibody against oxidized LDL predicting myocardial infarction. Arch. Intern. Med. 154, 2605-2609 (1994).
41. Bui MN, Sack MN, Moutsatsos G et al.: Autoantibody titers to ox-LDL in patients with coronary atherosclerosis. Am. Heart J. 131, 663-667 (1996).
42. van de Vijver LPL, Steyger R, van Poppel G et al.: Autoantibodies against mda-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122, 245-253 (1996).
43. Palinski W, Miller E, Witztum JL: Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherosclerosis. Proc. Natl Acad. Sci. USA 92, 821-825 (1995).
44. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al.: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscl. Thomb. Vasc. Biol. 16, 1074-1079 (1996).
45. Fredrikson GN, Soderberg I, Lindholm M et al.: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscl. Thromb. Vasc. Biol. 23, 879-884 (2003).
46. -/- mice. J. Am. Coll. Cardiol. 50, 2313-2318 (2007).
47. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL-receptor deficient mice with increased atherosclerosis. Arterioscl. Thromb. Vasc. Biol. 15, 1569-1576 (1995).
48. Walter MF, Jacob RF, Jeffers B et al.: Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease. A longitudinal analysis of the PREVENT study. J. Amer. Coll. Cardiol. 44, 1996-2000 (2004).
49. Salonen JT, Nyyssonen K, Salonen R et al.: Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 95, 840-845 (1997).
50. Hendrickson A, McKinstry LA, Lewis JK et al.: Ex vivo measures of LDL oxidative susceptibility predict coronary artery disease. Atherosclerosis 179, 147-153 (2005).
51. Rabini RA, Tesei M, Galeazzi T, Dousset N, Ferretti G, Mazzanti L: Increased susceptibility to peroxidation of VLDL from non-insulin-dependent diabetic patients: a possible correlation with fatty acid composition. Mol. Cell. Biochem. 199, 63-67 (1999).
52. McEneny J, O'Kane MJ, Moles KW et al.: Very low density lipoprotein subfractions in Type 2 diabetes mellitus: Alterations in composition and susceptibility to oxidation. Diabetologia 43, 485-493 (2000).
53. Ryglewicz D, Rodo M, Roszczynko M et al.: Dynamics of LDL oxidation in ischemic stroke patients. Acta Neurol. Scand. 105, 185-188 (2002).
54. Tribblbe DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six LDL subfractions of differing density and particle size. Atherosclerosis 93, 189-199 (1992).
55. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM: Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors 103-110 (2001).
56. Rudel LL, Shah R, Greene DG: Study of the atherogenic dyslipidemia induced by dietary cholesterol in rhesus monkeys (Macaca mulatta). J. Lipid Res. 20, 55-65 (1979).
57. Le N-A, Li X, Kyung S, Brown WV: Evidence for the in vivo generation of oxidatively modified epitopes in patients with documented CAD. Metabolism 49, 1271-1277 (2000).
58. Gradek Q, Harris M, Yahia N, Davis W, Le N-A, Brown WV: Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified LDL in patients with vascular disease. Am. J. Cardiol. 93, 881-885 (2004).
59. Louheranta AM, Porkkala-Sarataho EK, Nyyssonen MK, Salonen RM, Salonen JT: Linoleic acid intake and susceptibility of very-low-density and low-density lipoproteins to oxidation in men. Am. J. Clin. Nutr. 63, 698-703 (1996).
60. Ceriello A, Ruggle JA, Piconi L et al.: Effects of pramlitide on postprandial glucose excursion and measures of oxidative stress in patients with Type 1 diabetes. Diabetes Care 28, 632-637 (2005).
61. Ceriello A, Lush CW, Darsow T et al.: Pramlitide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diab. Metab. Res. Rev. 24, 103-108 (2008).
62. Tsimikas S, Bermark C, Beyer RW et al.: Temporal increases in plasma markers of oxidized LDL strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41, 360-370 (2003).
63. Tsimikas S, Lau HK, Han K-R et al.: Percutaneous coronary intervention results in acute increases in oxidized phospholipids and Lp(a). Short-term and long-term immunologic responses to ox-LDL. Circulation 109, 3164-3170 (2004).
64. Sawamura T, Kume N, Aoyama T et al.: An endothelial receptor for oxidized LDL, Nature 386, 73-77 (1997).
65. Endemann G, Stanton IW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized LDL. J. Biol. Chem. 268, 11811-11816 (1993).
66. Acton SL, Sherer PE, Lodish HF, Krieger M: Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269, 21003-21009 (1994).
67. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D: Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized LDL. Proc. Natl Acad. Sci. USA 93, 15833-14838 (1996).
68. Sun B, Boyanovsky BB, Connelly MA et al.: Distinct mechanisms for ox-LDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J. Lipid Res. 48, 2560-2570 (2007).
69. WIklundm O, Witztum JL, Carew TE, Pitman RC, Elam RL, Steinberg D: Turnover and tissue sites of degradation of glucosylated LDL in normal and immunized rabbits. J. Lipid Res. 28, 1098-1109 (1987).
70. Torzewski M, Shaw PX, K-Han R et al.: Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscl. Thromb. Vasc. Biol. 24, 2307-2312 (2004).
71. Briley-Saebo KC, Shaw PX, Mulder WJ et al.: Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117, 3206-3215 (2008).
72. Tsmikas S, Shortal BP, Witztum JL, Palinski W: In vivo uptake of radiolabeled MDA2, an oxidation specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscl. Thromb. Vasc. Biol. 20, 689-697 (2000).
73. Nishi K, Itabe H, Uno M et al.: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscl. Thromb. Vasc. Biol. 22, 1649-1654 (2002).
74. Tsimikas S, Aikawa M, Miller FJ Jr et al.: Increased plasma oxidized phospholipid: ApoB-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscl. Thromb. Vasc. Biol. 27, 175-181 (2007).
75. Ishigaki Y, Katagiri H, Gao J et al.: Impact of plasma ox-LDL removal on atherosclerosis. Circulation 118, 75-83 (2008).
76. Ky B, Burke A, Tsimikas S et al.: The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 51, 1653-1662 (2008).
77. Choi SY, Chae A, Miller E et al.: Relationship between biomarkers of oxidized LDL, statin therapy, quantitative coronary angiography, and atheroma volume. J. Am. Coll. Cardiol. 52, 24-32 (2008).
78. Esposito K, Giugliano D, Nappo F, Marfella R; for the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation 110, 214-219 (2004).
79. EC Tozer, Carew TE: Residence time of LDL in the normal and atherosclerotic rabbit aorta. Circulation Res. 80, 208-218 (1997).